Muhammad Shaalan Beg, MD

home / authors / muhammad-shaalan-beg-md

Articles

Closing Thoughts on Recent Data in GI Cancer

Rohit Gosain, MD;Rahul Gosain, MD;Muhammad Shaalan Beg, MD

July 26th 2023

Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key gastrointestinal cancer data updates discussed following the 2023 ASCO Annual Meeting.

IMbrave050: Adjuvant Therapy for High-Risk Hepatocellular Carcinoma

Rohit Gosain, MD;Rahul Gosain, MD;Muhammad Shaalan Beg, MD

July 26th 2023

The Oncology Brothers, joined by Muhammad Shaalan Beg, MD, share their thoughts on data from the IMbrave050 trial investigating adjuvant atezolizumab plus bevacizumab in patients with high-risk hepatocellular carcinoma.

NAPOLI-3: Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Rohit Gosain, MD;Rahul Gosain, MD;Muhammad Shaalan Beg, MD

July 26th 2023

A review of recent data from NAPOLI-3 comparing the NALIRIFOX chemotherapy regimen versus nab-paclitaxel plus gemcitabine for patients with metastatic pancreatic ductal adenocarcinoma.

NORPACT-1: Neoadjuvant Chemotherapy for Resectable Pancreatic Head Cancer

Rohit Gosain, MD;Rahul Gosain, MD;Muhammad Shaalan Beg, MD

July 26th 2023

Expert oncologists review recent data from the NORPACT-1 study on the use of neoadjuvant FOLFIRINOX chemotherapy for patients with resectable pancreatic head cancer.

PROSPECT: Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Rohit Gosain, MD;Rahul Gosain, MD;Muhammad Shaalan Beg, MD

July 26th 2023

Muhammad Shaalan Beg, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data from the PROSPECT trial investigating neoadjuvant therapy regimens for the treatment of locally advanced rectal cancer.